Alembic Pharmaceuticals Secures USFDA Approval with 180-Day Exclusivity for Binimetinib Tablets
Alembic Pharmaceuticals Ltd 路 Press Release 路 15 Nov 2026, 2:33 am
Alembic Pharmaceuticals Secures USFDA Approval with 180-Day Exclusivity for Binimetinib Tablets Alembic Pharmaceuticals received final USFDA approval for its ANDA for Binimetinib Tablets (15 mg and 45 mg), generic to Array BioPharma's Mektovi. As a first-to-file applicant with Paragraph IV certification, Alembic secured 180 days of generic drug exclusivity for both strengths. The drug addresses metastatic melanoma and metastatic NSCLC indications. According to IQVIA, Binimetinib tablets recorded an estimated market size of US$ 282 million for the 12 months ending Sep'26. Alembic now holds 248 cumulative USFDA approvals, comprising 230 final and 18 tentative approvals.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
